Genmab A/S (Genmab A/S) Total Assets : $5,163 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Genmab A/S Total Assets?

Genmab A/S's Total Assets for the quarter that ended in Dec. 2023 was $5,163 Mil.

During the past 12 months, Genmab A/S's average Total Assets Growth Rate was -8.20% per year. During the past 3 years, the average Total Assets Growth Rate was 12.20% per year. During the past 5 years, the average Total Assets Growth Rate was 23.80% per year. During the past 10 years, the average Total Assets Growth Rate was 50.20% per year.

During the past 13 years, Genmab A/S's highest 3-Year average Total Assets Growth Rate was 133.50%. The lowest was -55.50%. And the median was 29.30%.

Total Assets is connected with ROA %. Genmab A/S's annualized ROA % for the quarter that ended in Dec. 2023 was 7.34%. Total Assets is also linked to Revenue through Asset Turnover. Genmab A/S's Asset Turnover for the quarter that ended in Dec. 2023 was 0.13.

Genmab A/S Total Assets Historical Data

The historical data trend for Genmab A/S's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Total Assets Chart

Genmab A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

2,252.60

3,457.34

3,742.14

4,288.68

5,163.14

Genmab A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															4,288.68	4,371.85	4,653.44	5,042.86	5,163.14

Genmab A/S Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Genmab A/S's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	4624.861	+	538.275
	=	5,163

Genmab A/S's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	4624.861	+	538.275
	=	5,163

Genmab A/S (OTCPK:GNMSF) Total Assets Explanation

Total Assets is connected with ROA %.

Genmab A/S's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	374.552	/	( (5042.861	+	5163.136)	/ 2 )
	=	374.552	/	5102.9985
	=	7.34 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Genmab A/S's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	684.438	/	( (5042.861	+	5163.136)	/ 2 )
=	684.438	/	5102.9985
=	0.13

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Genmab A/S Total Assets Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (Genmab A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OTCPK:GNMSF) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.